Donna S Neuberg
Overview
Explore the profile of Donna S Neuberg including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
199
Citations
10550
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Amrein P, Preffer F, Fell G, Attar E, Narayan R, Blonquist T, et al.
Leuk Lymphoma
. 2025 Mar;
:1-11.
PMID: 40070233
Outcome for acute myeloid leukemia (AML) patients aged >60 years is poor. Targeting the proteasome in AML is attractive, since leukemia stem cells demonstrate sensitivity to proteasome inhibition in preclinical...
2.
Juhasz V, Quinaglia T, Drobni Z, Heemelaar J, Neuberg D, Han Y, et al.
JACC CardioOncol
. 2025 Feb;
7(2):125-137.
PMID: 39967198
Background: In the STOP-CA (Statins to Prevent the Cardiotoxicity From Anthracyclines) trial, atorvastatin preserved the left ventricular ejection fraction among patients with lymphoma treated with anthracyclines. The protective mechanisms are...
3.
Braun D, Moranzoni G, Chea V, McGregor B, Blass E, Tu C, et al.
Nature
. 2025 Feb;
639(8054):474-482.
PMID: 39910301
Personalized cancer vaccines (PCVs) can generate circulating immune responses against predicted neoantigens. However, whether such responses can target cancer driver mutations, lead to immune recognition of a patient's tumour and...
4.
Maurer K, Park C, Mani S, Borji M, Raths F, Gouin 3rd K, et al.
Sci Immunol
. 2025 Jan;
10(103):eadr0782.
PMID: 39854478
Understanding how intratumoral immune populations coordinate antitumor responses after therapy can guide treatment prioritization. We systematically analyzed an established immunotherapy, donor lymphocyte infusion (DLI), by assessing 348,905 single-cell transcriptomes from...
5.
Muskens K, Wieringa N, van Bergen M, Bense J, Te Pas B, de Pagter A, et al.
Blood Cancer Discov
. 2025 Jan;
6(2):110-118.
PMID: 39804695
As survival of HCT recipients continues to improve, late treatment effects gain importance. We demonstrate that pediatric HCT recipients show increased risk of CH compared with age-matched controls. Prospective studies...
6.
Shimony S, Raman H, Flamand Y, Keating J, Paolino J, Valtis Y, et al.
Blood Cancer J
. 2024 Nov;
14(1):191.
PMID: 39482298
Asparaginase (ASP)-containing regimens for acute lymphoblastic leukemia (ALL) are associated with venous thromboembolism (VTE). We evaluated the prevalence, risk factors, role of prophylaxis and clinical impact of VTE among adolescents...
7.
Walters M, Eapen M, Liu Y, El Rassi F, Waller E, Levine J, et al.
Blood Adv
. 2024 Oct;
9(5):955-965.
PMID: 39471440
Disease-modifying therapies are standard of care (SOC) for sickle cell disease (SCD), but hematopoietic cell transplantation (HCT) has curative potential. We compared outcomes prospectively through 2 years after biologic assignment...
8.
Maurer K, Grabski I, Houot R, Gohil S, Miura S, Redd R, et al.
Blood
. 2024 Sep;
144(24):2490-2502.
PMID: 39241199
Engineered cellular therapy with CD19-targeting chimeric antigen receptor T cells (CAR-Ts) has revolutionized outcomes for patients with relapsed/refractory large B-cell lymphoma (LBCL), but the cellular and molecular features associated with...
9.
Penter L, Cieri N, Maurer K, Kwok M, Lyu H, Lu W, et al.
Blood Cancer Discov
. 2024 Sep;
5(6):442-459.
PMID: 39236287
Combined tracking of clonal evolution and chimeric cell phenotypes could enable detection of the key cellular populations associated with response following therapy, including after allogeneic hematopoietic stem cell transplantation (HSCT)....
10.
Bewersdorf J, Shimony S, Shallis R, Liu Y, Berton G, Schaefer E, et al.
Blood Adv
. 2024 Jun;
8(18):4845-4855.
PMID: 38941537
Although intensive induction chemotherapy (IC) remains the standard of care for younger patients with acute myeloid leukemia (AML), hypomethylating agents + venetoclax (HMA/VEN) can lead to durable remission among older...